Daratumumab subcutaneous preparations for the treatment of multiple myeloma: CHMP takes a positive view
-
Last Update: 2020-06-24
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Genmab Pharmaceuticals today announced that the European Medicines Agency (EMA) Human Medicines Commission (CHMP) has issued a positive opinion on the use of daratumumab subcutaneous preparations for patients with relapsed multiple myelomaCHMP's positive opinion on daratumumab subcutaneous preparations applies to all currently approved indicationsDr Jan van de Winkel, chief executive of Genmab, said: "We are very pleased with the positive comments from CHMP that subcutaneous injections of daratumab will benefit patients with multiple myeloma in Europe."Phase III COLUMBA (MMY3012) studies and Phase II PLEIADES (MMY2040) studies have shown that daratumab's subcutaneous preparations are safe and effective in treating relapse, difficult-to-treat multiple myelomaThe main results of the COLU MBA study were published in February 2019Daratumab is a targeted CD38-monoclonal antibody used in patients with multiple myeloma who have previously been treated with protease inhibitors (PI) or immunomodulators such as Vemidli of Celgene, but still develop the disease
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
